Gene · 2204
Papers1,603
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
101 to 120 of 1,603
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| RhoA vesicle trafficking-mediated transglutaminase 2 membrane translocation promotes IgA1 mesangial deposition in IgA nephropathy. | JCI Insight | 2023 | 37811653 | PubTator, text mining | PubMed |
| The functional response of human monocyte-derived macrophages to serum amyloid A and Mycobacterium tuberculosis infection. | Front Immunol | 2023 | 37781389 | PubTator, text mining | PubMed |
| Immunoglobulin A vasculitis nephritis: Current understanding of pathogenesis and treatment. | World J Nephrol | 2023 | 37766840 | PubTator, text mining | PubMed |
| Macrophage Activation in Follicular Conjunctivitis during the COVID-19 Pandemic. | Microorganisms | 2023 | 37764042 | PubTator, text mining | PubMed |
| A Fully Human IgE Specific for CD38 as a Potential Therapy for Multiple Myeloma. | Cancers (Basel) | 2023 | 37760502 | PubTator, text mining | PubMed |
| A narrative review of potential drug treatments for nephritis in children with IgA vasculitis (HSP). | Clin Rheumatol | 2023 | 37755547 | PubTator, text mining | PubMed |
| Causal relationships between circulating inflammatory factors and IgA vasculitis: a bidirectional Mendelian randomization study. | Front Immunol | 2023 | 37753071 | PubTator, text mining | PubMed |
| Current Understanding of Complement Proteins as Therapeutic Targets for the Treatment of Immunoglobulin A Nephropathy. | Drugs | 2023 | 37747686 | PubTator, text mining | PubMed |
| Emerging significance and therapeutic targets of ferroptosis: a potential avenue for human kidney diseases. | Cell Death Dis | 2023 | 37739961 | PubTator, text mining | PubMed |
| Research progress on the mechanism of cholesterol-25-hydroxylase in intestinal immunity. | Front Immunol | 2023 | 37720208 | PubTator, text mining | PubMed |
| Justification of Universal Iron Supplementation for Infants 6-12 months in Regions with a High Prevalence of Thalassemia. | Mediterr J Hematol Infect Dis | 2023 | 37705528 | PubTator, text mining | PubMed |
| Present and Future of IgA Nephropathy and Membranous Nephropathy Immune Monitoring: Insights from Molecular Studies. | Int J Mol Sci | 2023 | 37685941 | PubTator, text mining | PubMed |
| Single-cell multi-omics topic embedding reveals cell-type-specific and COVID-19 severity-related immune signatures. | Cell Rep Methods | 2023 | 37671028 | PubTator, text mining | PubMed |
| Cell-targeted vaccines: implications for adaptive immunity. | Front Immunol | 2023 | 37662903 | PubTator, text mining | PubMed |
| Serum immunoglobulin and the threshold of Fc receptor-mediated immune activation. | Biochim Biophys Acta Gen Subj | 2023 | 37652365 | PubTator, text mining | PubMed |
| DENV-specific IgA contributes protective and non-pathologic function during antibody-dependent enhancement of DENV infection. | PLoS Pathog | 2023 | 37639455 | PubTator, text mining | PubMed |
| The Role of IgA in the Manifestation and Prevention of Allergic Immune Responses. | Curr Allergy Asthma Rep | 2023 | 37610671 | PubTator, text mining | PubMed |
| The IgA of hares (Lepus sp.) and rabbit confirms that the leporids IgA explosion is old and reveals a new case of trans-species polymorphism. | Front Immunol | 2023 | 37600766 | PubTator, text mining | PubMed |
| Design, optimization, production and activity testing of recombinant immunotoxins expressed in plants and plant cells for the treatment of monocytic leukemia. | Bioengineered | 2023 | 37598369 | PubTator, text mining | PubMed |
| Mutational analysis of hemoglobin genes and functional characterization of detected variants, through in-silico analysis, in Pakistani beta-thalassemia major patients. | Sci Rep | 2023 | 37580329 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2204/papers?page=6